“…Contrary to 21OHD, the heterozygotes from families of patients of classic or NC 11βOHD have no significant differences in HLA genotyping or hormonal profile compared to control population [58,59,86,87]. However, there are two mutations in heterozygous carriers (p.R366C, p.T401A) with evidence of reduced CYP11B1 activity by 23 to 37%, respectively [32].…”